The short version of Fragment designation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
In addition to its role as a trypsin inhibitor, in rats it has also been found to stimulate the release of CCK from the enteroendocrine cells of the small intestine, and it has been called "monitor peptide" in this context. CCK then acts on the gallbladder to release bile and on the pancreas to release digestive enzymes, which help to further break down the food. This coordinated response helps to ensure efficient digestion and absorption of nutrients.
Histology (also known as microanatomy or histoanatomy) is the branch of medicine that studies the microscopic anatomy of biological tissues. Histology is the microscopic counterpart to gross anatomy, which looks at larger structures visible without a microscope. Histopathology is the branch of histology that includes the microscopic identification and study of diseased tissue.
Creatine methyl ester is the methyl ester derivative of the amino acid creatine. It can be prepared by the esterification of creatine with methanol. By undergoing an esterification process with methanol, this compound seeks to enhance creatine's absorption rate in the body. Creatine esters, like creatine methyl ester, have been studied for their potential to improve bioavailability when compared to standard creatine monohydrate.
On 21 May 1917 Angelo Sereni, president of the Committee of the Jewish Communities, presented Sokolow to Sidney Sonnino, the Italian Minister of Foreign Affairs. He was also received by Paolo Boselli, the Italian prime minister. Sonnino arranged for the secretary general of the ministry to send a letter to the effect that, although he could not express himself on the merits of a program which concerned all the allies, "generally speaking" he was not opposed to the legitimate claims of the Jews. On his return journey, Sokolow met with French leaders again and secured a letter dated 4 June 1917, giving assurances of sympathy towards the Zionist cause by Jules Cambon, head of the political section of the French foreign ministry. This letter was not published, but was deposited at the British Foreign Office. Following the United States' entry into the war on 6 April, the British Foreign Secretary led the Balfour Mission to Washington, D.C., and New York, where he spent a month between mid-April and mid-May. During the trip he spent significant time discussing Zionism with Louis Brandeis, a leading Zionist and a close ally of Wilson who had been appointed as a Supreme Court Justice a year previously.
Sources: en.wikipedia.org
== External links == Glucagon-Like Peptide-2 Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
== As a drug target == Inhibitors of MTHFR and antisense knockdown of the expression of the enzyme have been proposed as treatments for cancer. The active form of folate, L-methylfolate, may be appropriate to target for conditions affected by MTHFR polymorphisms.
NADPH deficiency can cause a dysfunction in glutathione peroxidase which is an enzyme that converts hydrogen peroxide (a reactive oxygen species) into water. G6PD (glucose-6-phosphate dehydrogenase) deficiency exacerbated by administration of oxidant drugs (e.g., primaquine, dapsone, quinidine) can also result in Heinz bodies. G6PD deficient red cells in combination with high levels of oxidants causes a cross-linking of sulfhydryl groups on globin chains which causes a denaturing and formation of Heinz body precipitates. Heinz bodies can also be found in chronic liver disease. Alpha-thalassemia. Normal adult hemoglobin is composed of two alpha and two beta chains. Alpha thalassemia patients have partial or complete defects in alpha globin production, leading to a relative abundance of beta globin chains in the cell. These excess beta globin chains aggregate to form HbH, which has decreased solubility and precipitates in the red blood cell cytoplasm. This is not direct damage to hemoglobin per se, but rather a perturbation in the quaternary structure of hemoglobin. The presence of Heinz bodies may also be a feature of hyposplenism or asplenia, when a damaged or absent spleen cannot remove these damaged cells from circulation.
In another, there is a wider reaction, involving the blood or other organs. This is called a systemic allergy. The result can be hives or red patches all over the skin or may feel changes in heart rate or breathing rate. A doctor may treat the underlying allergy by prescribing purified insulins or by desensitization. The acute symptoms may also require treatment, possibly by anti-histamines. See also: Desensitization. Insulin antagonists Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it. Glucagon is, therefore, an antagonist of insulin. Insulin binding When insulin attaches itself to something else. This can occur in two ways. First, when a cell needs energy, insulin can bind with a special purpose receptor on the surface of a cell (about 2/3 of human body cells, including muscles, but not including nerve cells). The cell then can bring glucose (sugar) inside; thus enabling energy production in the cell. Some cells can store glucose internally (liver cells and muscle cells primarily), but others, most importantly, nerve cells, cannot. With the help of insulin, the cell can absorb 'fuel' and proceed to do its work. But sometimes the body acts against itself. In this second case, the insulin binds with the proteins that are supposed to tag antigens (substances or fragments of cells) which are foreign to the body (i.e., antibodies). If the insulin is an injected form and not made internally, the body may see the insulin as an outside or "foreign" substance.
=== Okinawa, Japan === Between 1995 and 1996, U.S. Marine AV-8B Harrier jets accidentally fired more than 1,500 DU rounds at the Tori Shima gunnery range. The military did not notify the Japanese government until January 1997.
Sources: en.wikipedia.org
== Adverse effects == As with other SGLT2 inhibitors, canagliflozin is associated with increased incidence of urinary tract infections, fungal infections of the genital area, thirst, elevations in LDL cholesterol, increased urination and episodes of low blood pressure. Rarely, use of canagliflozin is associated with necrotizing fasciitis of the perineum, also called Fournier gangrene. There are concerns that it may also increase the risk of diabetic ketoacidosis. Possible cardiovascular problems are an ongoing issue with gliflozin drugs. The pre-specified endpoint for cardiovascular safety in the canagliflozin clinical development program was "Major Cardiovascular Events Plus", defined as the occurrence of cardiovascular death, non-fatal myocardial infarctions, non-fatal strokes, or unstable angina leading to hospitalization. This endpoint occurred in more people in the placebo group (20.5%) than in the canagliflozin treated group (18.9%). Nonetheless, a United States Food and Drug Administration (FDA) advisory committee expressed concern regarding the cardiovascular safety of canagliflozin. A greater number of cardiovascular events was observed during the first 30 days in study subjects who received canagliflozin (0.45%) compared those who received placebo (0.07%), suggesting an early period of increased cardiovascular risk. In addition, there was an increased risk of stroke in subjects who received canagliflozin. However, none of these effects were statistically significant. Additional cardiovascular safety data from another ongoing study are expected in 2015.
==== August 2008 ==== Nezavisimaya Gazeta reported in June 2008 that when Chechen peacekeepers from Vostok Battalion began serving in South Ossetia in the autumn of 2007, they began arresting armed people with fake peacekeeping IDs. However, the Chechens were soon ordered to cease the arrest of the impostors and armed people with unknown affiliations were now freely roaming South Ossetia. On 4 August 2008, Life.ru reported that after the end of the "Kavkaz 2008" exercises, the paratroopers from Pskov remained to occupy the key positions on the Roki and Mamison passes on the border. Several battalions of 58th Army were deployed close to the border and the South Ossetian sources told the newspaper that the deployment of troops began on the night of 2–3 August 2008. Life.ru reported, "The deployment of the Russian military hardware near the Roki Tunnel will allow as soon as possible to move troops to help the peacemaking forces." On 6 August 2008, OsRadio reported that the volunteers were also arriving in Tskhinvali from Moscow. On 26 September 2008, Trud reported on the special battalion Vostok. One member of the battalion Khamzat said, "See what the "Red Star" wrote about us: Volunteers from neighboring republics arrive in South Ossetia. So we are volunteers?!" Khamzat added, "We are the regular subunit of 291-th Regiment of 42nd Guards Motor Rifle Division of the North Caucasus Military District. And we only act on orders." On 8 August 2008, Nezavisimaya Gazeta published an article by journalist who had spent previous three days in Chechnya.
Complaints about marketed products must be examined, the causes of quality defects must be investigated, and appropriate measures must be taken with respect to the defective products and to prevent recurrence. Good manufacturing practice is recommended with the goal of safeguarding the health of consumers and patients as well as producing quality products. In the United States, a food or drug may be deemed "adulterated" if it has passed all of the specifications tests but is found to be manufactured in a facility or condition which violates or does not comply with current good manufacturing guideline. GMP standards are not prescriptive instructions on how to manufacture products. They are a series of performance based requirements that must be met during manufacturing. When a company is setting up its quality program and manufacturing process, there may be many ways it can fulfill GMP requirements. It is the company's responsibility to determine the most effective and efficient quality process that both meets business and regulatory needs. Regulatory agencies have recently begun to look at more fundamental quality metrics of manufacturers than just compliance with basic GMP regulations. US-FDA has found that manufacturers who have implemented quality metrics programs gain a deeper insight into employee behaviors that impact product quality.
== Further reading == ABC News gallery of Cheese seized by the Dallas ISD Pantazi, Andrew. "‘Cheese’ heroin led Dallas 13-year-old to a life on the edge." The Dallas Morning News. 29 December 2012. Updated 30 December 2012. Dave Montgomery. "Law enforcement worries 'cheese heroin' could spread," McClatchy Newspapers, July 18, 2007. Maxwell, Jane C., PhD (Senior Research Scientist, University of Texas at Austin Gulf Coast Addiction Technology Transfer Center). "“Cheese” Heroin: Status as of May 2, 2007" (Archive) Merlan, Anna. "In Suburban Dallas, Loosening "Cheese" Heroin's Deadly Grip Archived 2013-10-13 at the Wayback Machine." Dallas Observer. July 28, 2011. Merlan, Anna. "Why Does Dallas Keep Forgetting About its Cheese-Heroin Problem? Archived 2012-12-24 at the Wayback Machine" Dallas Observer. May 21, 2012. "Dallas Man Sentenced to a Total of 240 Months in Federal Prison for Role in Heroin Distribution Conspiracies." (Archive[link removed]) United States Department of Justice. November 5, 2013. Tracy Sabo. "Deadly $2 heroin targets teens," CNN, June 12, 2007. "New Drug Hits the Street? A 'Poor Man's Heroin' For Kids", Pine Magazine, June 12, 2007.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.